Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Myeloproliferative Neoplasms
•
Hematology
What aspirin dose do you favor for thrombotic prophylaxis in myeloproliferative neoplasms?
81 mg vs 162 mg
Answer from: at Academic Institution
I generally use 81 mg twice a day. If they have had a thrombotic event, or have microvascular symptoms, then I use 81 mg BiD.
Sign In
or
Register
to read more
14664
Related Questions
For essential thrombocythemia with an indication for aspirin, would you defer therapy if they are on celecoxib?
How would you manage a patient with polycythemia and MPN symptoms (aquagenic pruritus, fatigue) that is JAK2/CALR/MPL negative but peripheral blood NGS positive for IDH2?
Do you forego aspirin use in essential thrombocythemia if they are already on clopidogrel?
How does triple-negative status influence your management of ET?
What experience have you had with familial clustering of polycythemia vera?
For patients with intermediate or lower risk essential thrombocythemia with plt >1000 but no symptoms, do you favor aspirin only therapy or aspirin and cytoreduction?
How do you decide the dose of aspirin to use in MPN patients?
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
How do you anticipate rusfertide will be used in the management of polycythemia vera?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?